In the BioHarmony Drug Report Database
Epoprostenol
Flolan, Veletri (epoprostenol) is a small molecule pharmaceutical. Epoprostenol was first approved as Flolan on 1995-09-20. It is used to treat arteriosclerosis, peripheral vascular diseases, pulmonary hypertension, purpura, and respiratory distress syndrome amongst others in the USA. The pharmaceutical is active against prostaglandin E2 receptor EP1 subtype. In addition, it is known to target prostaglandin E2 receptor EP4 subtype and prostacyclin receptor. Flolan’s patent is valid until 2027-03-15 (FDA).
Trade Name
|
Flolan, Veletri |
|---|---|
Common Name
|
epoprostenol |
ChEMBL ID
|
CHEMBL1139 |
Indication
|
arteriosclerosis, peripheral vascular diseases, pulmonary hypertension, purpura, respiratory distress syndrome, systemic scleroderma |
Drug Class
|
Prostaglandins |
Image (chem structure or protein)